Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial.
Kathryn Maitland, Elizabeth C George, Jennifer A Evans...
https://pubmed.ncbi.nlm.nih.gov/23496872/Actively Recruiting
Led by International Centre for Diarrhoeal Disease Research, Bangladesh · Updated on 2025-04-16
135
Participants Needed
1
Research Sites
17 weeks
Total Duration
Diarrhea is a major cause of death in children under five years old, especially when combined with severe acute malnutrition SAM and shock. This study evaluates the best treatment for children with SAM or severe underweight who have fluid refractory shock and diarrhea, comparing blood transfusion with dopamine versus blood transfusion with adrenaline after standard fluid therapy fails. The trial aims to reduce the high mortality rates seen in these children, particularly in settings like the Dhaka hospital where death rates are very high. The trial is a randomized, controlled study with two treatment groups. One group receives a blood transfusion at 10 mLkg over 2-3 hours plus dopamine starting at 8 microgramskgmin, increasing as tolerated. The other group receives the same blood transfusion plus adrenaline starting at 0.1 microgramskgmin, also with dose escalation. Both groups receive hydrocortisone alongside the study treatments. The study focuses on children aged 1 to 59 months with severe malnutrition and fluid refractory shock. Participants will be monitored closely during the study for outcomes including death rate over 28 days, treatment failure, heart and lung function, need for mechanical ventilation, and length of hospital and ICU stay. Assessments include heart function measurements and blood pressure stabilization. The study involves follow-up for an average of seven days during hospitalization, with data collection on recovery time and survival. The total participation period extends through hospital discharge and includes safety monitoring.
CONDITIONS
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
M
Monira Sarmin, MBBS, MCPS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
International Centre for Diarrhoeal Disease Research, Bangladesh
Lead Sponsor
University of British Columbia
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 days or until discharge
Participants receive a blood transfusion and either dopamine or adrenaline to manage fluid refractory shock following WHO standard fluid therapy. Hydrocortisone is also administered as part of treatment.
Daily visits during treatment period
Duration - Up to 28 days (± 3 days)
Participants are monitored for safety and recovery outcomes including survival, heart function, and hospital stay after treatment ends.
Follow-up visits through 28 days post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kathryn Maitland, Elizabeth C George, Jennifer A Evans...
https://pubmed.ncbi.nlm.nih.gov/23496872/Monira Sarmin, Tahmeed Ahmed, Pradip K Bardhan...
https://pubmed.ncbi.nlm.nih.gov/24661049/T Ahmed, M Ali, M M Ullah...
https://pubmed.ncbi.nlm.nih.gov/10371570/Andréa M C Ventura, Huei Hsin Shieh, Albert Bousso...
https://pubmed.ncbi.nlm.nih.gov/26323041/Karthik Narayanan Ramaswamy, Sunit Singhi, Muralidharan Jayashree...
https://pubmed.ncbi.nlm.nih.gov/27673385/Abdur Razzaque Sarker, Marufa Sultana, Rashidul Alam Mahumud...
https://pubmed.ncbi.nlm.nih.gov/29318195/R L Guerrant, J B Schorling, J F McAuliffe...
https://pubmed.ncbi.nlm.nih.gov/1632474/Mohammod J Chisti, Mark A C Pietroni, Jonathan H Smith...
https://pubmed.ncbi.nlm.nih.gov/21627690/Zoe K McQuilten, D James Cooper
https://pubmed.ncbi.nlm.nih.gov/31821418/Scott L Weiss, Mark J Peters, Waleed Alhazzani...
https://pubmed.ncbi.nlm.nih.gov/32032273/International Centre for Diarrhoeal Disease Research, Bangladesh
Lead Sponsor
University of British Columbia
Collaborating Sponsor